Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, SS-31 improves mitochondrial bioenergetics, reduces oxidative stress, and shows protective effects in models of ischemia-reperfusion, neurodegeneration, and other mitochondrial disorders4637137.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, SS-31 is a mitochondria-targeted tetrapeptide, d-Arg-dimethylTyr-Lys-Phe-NH2, that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, improving electron transport, and reducing ROS production4637137143.
Liraglutide
GCG
SS-31
Not assigned in the current dataset.
Liraglutide and SS-31 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas SS-31 is more often associated with the realm of Aging and longevity and Cardiovascular health. They also influence different molecular systems, with Liraglutide tracking more closely to GLP-1 receptor while SS-31 centers more on Mitochondrial membrane. Liraglutide has a more synthetic analog origin, while SS-31 is closer to synthetic design background and their development context also differs, with Liraglutide approved while SS-31 is in Clinical phase 2. Liraglutide takes the form of a peptide conjugate, whereas SS-31 is closer to a linear peptide, Liraglutide carries palmitoylation features, while SS-31 instead reflects d-amino acid substitution and amidation changes; while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and SS-31 showing cationic amphipathic features.